Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oncolytic virus therapy using genetically engineered herpes simplex viruses.

Tomoki Todo1

  • 1Molecular Neurosurgery Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA. toudou-nsu@umin.ac.jp

Human Cell
|April 22, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1.

Molecular therapy. Oncology·2026
Same author

Oncolytic Herpes Virus G47∆ Potentiates ADCC-Inducing Molecular Targeted Therapy via Coordinated Activation of Innate and Adaptive Immune Responses.

Molecular cancer therapeutics·2026
Same author

Triple-Mutated HSV-1 Expressing Soluble B7-1 Plus CTLA-4 Blockade Suppresses Lymph Node Metastasis in Tongue Cancer.

Cancer science·2026
Same author

MicroRNA-138 regulation promotes the efficacy of oncolytic herpes virus G47Δ for malignant brain tumor therapy.

Molecular therapy. Oncology·2026
Same author

Multihit Somatic Mosaicism of <i>TP53</i> Pathogenic Variants in a Patient Mimicking Li-Fraumeni Syndrome.

JCO precision oncology·2025
Same author

Epithelial-Mesenchymal Transition and Genetically Driven Early Tumor Seedings in Extraneural Metastasis of Glioblastoma.

Cancer science·2025
Same journal

Bone marrow mesenchymal stem cell-derived exosomes exert therapeutic effects on inflammatory bowel disease through miR-148a-3p/Ets-1-dependent inhibition of pyroptosis.

Human cell·2026
Same journal

A model of Helicobacter infection using an artificial liver constructed by a radial-flow bioreactor.

Human cell·2026
Same journal

CNOT9 affects hepatocellular carcinoma proliferation and cell cycle through the PTEN/AKT/p53 signaling pathway.

Human cell·2026
Same journal

The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRAS<sup>G12C</sup> mutation.

Human cell·2026
Same journal

TRERNA1-mediated acetylation represses ferroptosis of non-small cell lung cancer cells via the KAT6A/H3K23ac/TRIM24-PIK3CA pathway.

Human cell·2026
Same journal

When fatty liver fuels kidney cancer: the THRB connection.

Human cell·2026
See all related articles

Oncolytic virus therapy, particularly using Herpes simplex virus type 1 (HSV-1) vectors, shows promise for cancer treatment. These engineered viruses selectively target and destroy tumor cells, offering a potential new therapeutic option.

Area of Science:

  • Oncolytic virotherapy
  • Cancer gene therapy
  • Viral oncology

Background:

  • Oncolytic viruses are engineered to selectively infect and kill cancer cells.
  • Herpes simplex virus type 1 (HSV-1) vectors offer advantages due to their genetic tractability and tumor-selective replication.
  • HSV-1 vectors can induce antitumor immunity and deliver multiple therapeutic transgenes.

Purpose of the Study:

  • To review the potential of oncolytic Herpes simplex virus type 1 (HSV-1) vectors in cancer therapy.
  • To highlight the safety and efficacy of HSV-1 based on clinical trials.
  • To discuss strategies for enhancing oncolytic HSV-1 efficacy.

Main Methods:

  • Review of existing literature on oncolytic HSV-1 vectors.
  • Analysis of clinical trial data for HSV-1 based cancer therapies.

Related Experiment Videos

  • Discussion of genetic engineering approaches for improved vector design.

    • Main Results:

    • Replication-competent HSV-1 vectors have demonstrated safety in human clinical trials, including for brain tumors.
    • HSV-1 vectors exhibit selective tumor cell lysis, amplified gene delivery, and induction of antitumor immunity.
    • Early studies show feasibility and safety of HSV-1 vector administration in patients.

    Conclusions:

    • Oncolytic HSV-1 vectors represent a promising therapeutic strategy for various cancers.
    • Ongoing research focuses on next-generation vectors and combination therapies to improve treatment outcomes.
    • Further development is expected to establish oncolytic virotherapy as a key cancer treatment modality.